Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA evaluates orlistat

This article was originally published in The Tan Sheet

Executive Summary

FDA is evaluating "rare reports" of hepatitis and liver-related laboratory abnormalities in people taking orlistat - the active ingredient, at 60 mg, in GlaxoSmithKline's OTC weight-loss drug alli. "Because of a lack of information in the reports, at this time, it is not possible to know the degree to which orlistat is responsible for the reported liver problems," an FDA spokeswoman said in an e-mail June 4. The agency is working with GSK to obtain post-marketing safety adverse events associated with orlistat, she added. This evaluation of orlistat, which is also the active ingredient, at 120 mg, in Roche's prescription Rx diet drug Xenical, comes as FDA continues investigating whether adverse event reports of rectal bleeding signal a potential serious risk identified with the ingredient (1"The Tan Sheet" Feb. 9, 2009, p. 8)


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts